Table 1.
Baseline characteristics in patients enrolled in DAPA-CKD with FSGS
| Characteristic | Dapagliflozin (N = 45) | Placebo (N = 59) | Total (N = 104) |
|---|---|---|---|
| Age (years) | 52.2 (14.2) | 55.4 (14.3) | 54.0 (14.3) |
| Sex, female, n (%) | 13 (28.9) | 21 (35.6) | 34 (32.7) |
| Race, n (%) | |||
| Asian | 8 (17.8) | 22 (37.3) | 30 (28.8) |
| Black or African American | 5 (11.1) | 2 (3.4) | 7 (6.7) |
| White | 28 (62.2) | 30 (50.8) | 58 (55.8) |
| Other | 4 (8.9) | 5 (8.5) | 9 (8.7) |
| Weight (kg) | 89.9 (18.2) | 81.7 (20.4) | 85.3 (19.8) |
| BMI (kg/m2) | 30.7 (6.5) | 28.7 (5.8) | 29.6 (6.1) |
| Blood pressure (mmHg) | |||
| Systolic | 127.0 (15.2) | 129.0 (14.7) | 128.2 (14.9) |
| Diastolic | 75.7 (9.8) | 76.1 (9.0) | 75.9 (9.3) |
| HbA1c, % | 5.7 (0.5) | 6.0 (1.1) | 5.9 (0.9) |
| eGFR (mL/min/1.73 m2) | 40.3 (10.6) | 43.2 (12.1) | 41.9 (11.5) |
| Haemoglobin (g/L) | 129.9 (16.1) | 133.3 (16.9) | 131.8 (16.6) |
| Serum potassium (mEq/L) | 4.6 (0.5) | 4.6 (0.4) | 4.6 (0.5) |
| Median UACR (interquartile range) | 997 (736–2290) | 1410 (769–2170) | 1248 (749–2211) |
| Type 2 diabetes, n (%) | 5 (11.1) | 15 (25.4) | 20 (19.2) |
| Heart failure, n (%) | 2 (4.4) | 0 (0) | 2 (1.9) |
| Prior medication, n (%) | |||
| ACEi | 17 (37.8) | 21 (35.6) | 38 (36.5) |
| ARB | 28 (62.2) | 36 (61.0) | 64 (61.5) |
| Diuretic | 19 (42.2) | 16 (27.1) | 35 (33.7) |
| Statin | 28 (62.2) | 45 (76.3) | 73 (70.2) |
Data are mean (SD) unless otherwise stated.
BMI, body mass index.